Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-24 20:30 • The Motley Fool Neutral Axe Cap view: Neutral

Bristol Myers Squibb's 4.1% dividend yield is sustainable in the near term, with earnings and free cash flow covering the payout more than twice over. However, the company faces a significant patent cliff as key drugs like Eliquis and Opdivo lose exclusivity by 2028, threatening roughly half of total revenue. While the dividend appears safe for now, investors should monitor how management navigates these challenges, potentially through slower dividend growth.

Axe note: BMY pays a reliable dividend today, but looming patent losses cast a shadow on future payouts.

2026-07-24 20:23 • The Motley Fool Neutral Axe Cap view: Selective

Intel reported strong Q2 2026 results with 25% year-over-year revenue growth to $16.1 billion and a swing to $0.42 adjusted EPS profitability, driven by AI and data center demand. Despite initial 12% after-hours gains, the stock fell below Thursday's closing price by Friday as investors reassessed the company's 60x P/E valuation, which assumes sustained high growth rates.

Axe note: Intel’s strong Q2 growth clashes with a valuation too rich for comfort.

2026-07-24 20:22 • The Motley Fool Positive Axe Cap view: Selective

Booz Allen Hamilton shares surged 10.49% after reporting strong Q1 2027 results with adjusted EPS of $1.81 beating analyst expectations of $1.49, despite slightly missing revenue estimates. The company generated $261 million in free cash flow (up 172% YoY) and provided 2027 guidance of $11.2-11.7 billion in revenue with adjusted EBITDA of $1.24-1.29 billion. Trading at 7x operating cash flow versus a five-year average of 16x, the stock appears undervalued.

Axe note: Strong cash flow and low valuation propelled Booz Allen’s share rally, sending a clear signal for value hunting on the JSE.